A steroid injection for a pimple is an intralesional corticosteroid injection, meaning a clinician injects dilute steroid directly into one large inflamed nodule or cyst. It works as add-on care for occasional stubborn lesions, not as standalone treatment for widespread acne, and often reduces inflammation within 24-48 hours. Daily topical and systemic care continues around the injection. The shot targets the selected bump, while routine treatment manages the rest of the skin.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who qualifies and who does not?
- What happens during the visit?
- How strong is the evidence?
- What are the risks and safety rules?
Who qualifies and who does not?
The American Academy of Dermatology recommends intralesional corticosteroid injections as adjuvant good clinical practice for acne vulgaris, combined with topical and systemic agents, according to the AAD guideline update. That means the injection supports regular care. It does not replace it.
AAD guidance describes intralesional triamcinolone acetonide as established treatment for occasional or stubborn inflamed nodulocystic lesions. Nodulocystic means large, deep, painful bumps or cysts. It is not for patients with many widespread lesions.
What happens during the visit?
Clinical practice descriptions report dermatologists inject dilute triamcinolone directly into individual large nodules or cysts with a very fine needle. Inflammation often looks calmer within 24-48 hours. One visit usually treats one or a few selected bumps.
Published dosing favors low concentrations to limit local tissue injury. Facial cystic acne is often treated at about 1-2 mg per mL. Non-facial lesions are often treated at about 2-3 mg per mL.
How strong is the evidence?
A systematic review of randomized and primary studies found intralesional triamcinolone 0.63-2.5 mg per mL effective, safe, and rapidly responsive for nodulocystic acne. Lower concentrations worked as well as higher ones. That finding supports starting low rather than using stronger mixes.
The evidence base remains small. The UK National Institute for Health and Care Excellence found only small, high-bias trials, including an eight-patient study where betamethasone showed no significant benefit over saline at one week or one month, according to the NICE evidence review. Readers should view fast shrinkage as likely but not guaranteed.
What are the risks and safety rules?
Reported local risks include skin and fat atrophy with dimpling, light spots called hypopigmentation, visible vessels called telangiectasia, infection, and sterile abscess. Atrophy means thinning or a dent at the site.
Hypopigmentation risk rises with superficial placement, especially in darker skin. FDA prescribing information limits Kenalog-10 to intra-articular or intralesional use only and warns against intravenous, intramuscular, ocular, epidural, or intrathecal use, with blindness reports after facial intralesional injections, according to the FDA prescribing information. Seek treatment only from a qualified clinician who gives acne injections routinely.
- Ask about the planned concentration and injection depth
- Mention darker skin tone, keloid history, infection signs, and diabetes
- Report a dent, lasting light spot, spreading redness, pain, or pus
- Keep follow-up topical and systemic care as prescribed